On Tuesday, Piper Sandler maintained its positive stance on Arrowhead Pharmaceuticals (NASDAQ:ARWR), reiterating an Overweight rating with a $62.00 price target. The biopharmaceutical company, known for its RNA interference therapeutics, has recently filed a New Drug Application (NDA) for plozasiran aimed at treating Familial Chylomicronemia Syndrome (FCS), potentially marking its first product approval and commercial launch projected for 2025.
The filing was supported by Phase III PALISADE trial data presented at the American Heart Association (AHA) meeting. Results indicated that plozasiran achieved the primary endpoint, significantly reducing triglycerides by 80% in FCS patients at 10 months. Additionally, the treatment was associated with a substantial 83% decrease in the risk of acute pancreatitis. These findings were statistically significant, bolstering confidence in the drug's efficacy.
Further supporting evidence came from the Phase II MUIR and SHASTA-2 OLE studies, where plozasiran demonstrated sustained triglyceride reductions of 73% and 86% over 15 months, alongside favorable changes in other lipid markers without adversely affecting LDL cholesterol or Lp(a) levels.
Arrowhead is not resting on its laurels, as it continues to advance its pipeline with ongoing Phase III SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia (SHTG), the MUIR-3 trial in homozygous genetic triglyceridemia (HGT), and plans for the CAPITAN cardiovascular outcomes trial (CVOT) to expand plozasiran's label.
Financially, the company is positioned on solid ground with a pro forma cash balance of approximately $837 million, which does not include the expected burn for the fourth fiscal quarter of 2024. Piper Sandler's reiterated Overweight rating reflects a vote of confidence in Arrowhead's strategic direction and pipeline potential.
In other recent news, Arrowhead Pharmaceuticals announced the submission of a New Drug Application to the FDA for plozasiran, a potential treatment for familial chylomicronemia syndrome. Based on successful Phase 3 trials, the drug has already received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation by the FDA. The company plans to seek approval for plozasiran in other markets in 2025.
In the same vein, Arrowhead reported a net loss of $170.8 million for its fiscal 2024 third-quarter, while cash and investments totaled $436.7 million. To support its pipeline development, Arrowhead secured a $400 million loan from Sixth Street.
Analyst ratings on the company have been mixed, with H.C. Wainwright and TD Cowen reiterating a Buy rating, while Goldman Sachs (NYSE:GS), Citi, and Piper Sandler maintained their Neutral, Neutral, and Overweight ratings respectively.
These are recent developments in Arrowhead's ongoing efforts to improve patient outcomes. The company is also advancing its central nervous system-targeted RNA interference programs, with plans to commence the Phase 1 clinical development of ARO-ATXN2 in the first quarter of 2025.
InvestingPro Insights
While Piper Sandler maintains an optimistic outlook on Arrowhead Pharmaceuticals, recent InvestingPro data reveals some challenging financial metrics. The company's market cap stands at $2.36 billion, but it's currently operating at a loss with a negative P/E ratio of -4.39 over the last twelve months. This aligns with an InvestingPro Tip indicating that Arrowhead is not profitable over the last twelve months.
Despite the promising pipeline developments mentioned in the article, InvestingPro data shows a significant revenue decline of -92.33% in the last twelve months. This steep drop is reflected in another InvestingPro Tip, which notes that analysts anticipate a sales decline in the current year.
On a positive note, Arrowhead's liquid assets exceed its short-term obligations, suggesting some financial stability in the near term. This could be crucial as the company progresses towards potential product approval and commercial launch in 2025.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Arrowhead Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.